181 related articles for article (PubMed ID: 30345538)
1. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.
Niccolini F; Mencacci NE; Yousaf T; Rabiner EA; Salpietro V; Pagano G; Balint B; Efthymiou S; Houlden H; Gunn RN; Wood N; Bhatia KP; Politis M
Mov Disord; 2018 Dec; 33(12):1961-1965. PubMed ID: 30345538
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
[TBL] [Abstract][Full Text] [Related]
3. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
[TBL] [Abstract][Full Text] [Related]
4. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Schülke JP; Brandon NJ
Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
[TBL] [Abstract][Full Text] [Related]
5. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
6. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
[TBL] [Abstract][Full Text] [Related]
7. Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.
Diggle CP; Sukoff Rizzo SJ; Popiolek M; Hinttala R; Schülke JP; Kurian MA; Carr IM; Markham AF; Bonthron DT; Watson C; Sharif SM; Reinhart V; James LC; Vanase-Frawley MA; Charych E; Allen M; Harms J; Schmidt CJ; Ng J; Pysden K; Strick C; Vieira P; Mankinen K; Kokkonen H; Kallioinen M; Sormunen R; Rinne JO; Johansson J; Alakurtti K; Huilaja L; Hurskainen T; Tasanen K; Anttila E; Marques TR; Howes O; Politis M; Fahiminiya S; Nguyen KQ; Majewski J; Uusimaa J; Sheridan E; Brandon NJ
Am J Hum Genet; 2016 Apr; 98(4):735-43. PubMed ID: 27058446
[TBL] [Abstract][Full Text] [Related]
8. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
9. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
[TBL] [Abstract][Full Text] [Related]
10. De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions.
Mencacci NE; Kamsteeg EJ; Nakashima K; R'Bibo L; Lynch DS; Balint B; Willemsen MA; Adams ME; Wiethoff S; Suzuki K; Davies CH; Ng J; Meyer E; Veneziano L; Giunti P; Hughes D; Raymond FL; Carecchio M; Zorzi G; Nardocci N; Barzaghi C; Garavaglia B; Salpietro V; Hardy J; Pittman AM; Houlden H; Kurian MA; Kimura H; Vissers LE; Wood NW; Bhatia KP
Am J Hum Genet; 2016 Apr; 98(4):763-71. PubMed ID: 27058447
[TBL] [Abstract][Full Text] [Related]
11. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
[TBL] [Abstract][Full Text] [Related]
12. Expanding the genotype-phenotype landscape of PDE10A-associated movement disorders.
Bohlega S; Abusrair AH; Al-Qahtani Z; Guzmán-Vega FJ; Ramakrishnan R; Aldosari H; Aldakheel A; Al-Qahtani S; Monies D; Arold ST
Parkinsonism Relat Disord; 2023 Mar; 108():105323. PubMed ID: 36805523
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study.
Persson J; Szalisznyó K; Antoni G; Wall A; Fällmar D; Zora H; Bodén R
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):451-459. PubMed ID: 31119377
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107.
Marques TR; Natesan S; Niccolini F; Politis M; Gunn RN; Searle GE; Howes O; Rabiner EA; Kapur S
Am J Psychiatry; 2016 Jul; 173(7):714-21. PubMed ID: 26892941
[TBL] [Abstract][Full Text] [Related]
15. Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
Tejeda GS; Whiteley EL; Deeb TZ; Bürli RW; Moss SJ; Sheridan E; Brandon NJ; Baillie GS
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):677-688. PubMed ID: 31871190
[TBL] [Abstract][Full Text] [Related]
16. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [
Svedberg MM; Varnäs K; Varrone A; Mitsios N; Mulder J; Gulyás B; Beaumont V; Munoz-Sanjuan I; Zaleska MM; Schmidt CJ; Halldin C; Mrzljak L
Brain Res; 2019 May; 1711():140-145. PubMed ID: 30664847
[TBL] [Abstract][Full Text] [Related]
17. A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea.
Salpietro V; Perez-Dueñas B; Nakashima K; San Antonio-Arce V; Manole A; Efthymiou S; Vandrovcova J; Bettencourt C; Mencacci NE; Klein C; Kelly MP; Davies CH; Kimura H; Macaya A; Houlden H
Mov Disord; 2018 Mar; 33(3):482-488. PubMed ID: 29392776
[TBL] [Abstract][Full Text] [Related]
18. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
Niccolini F; Foltynie T; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Kapur S; Rabiner EA; Gunn RN; Piccini P; Politis M
Brain; 2015 Oct; 138(Pt 10):3003-15. PubMed ID: 26210536
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions.
Mango D; Bonito-Oliva A; Ledonne A; Nisticò R; Castelli V; Giorgi M; Sancesario G; Fisone G; Berretta N; Mercuri NB
Neuropharmacology; 2014 Jan; 76 Pt A():127-36. PubMed ID: 23973317
[TBL] [Abstract][Full Text] [Related]
20. No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
Schöls L; Reimold M; Seidel K; Globas C; Brockmann K; Hauser TK; Auburger G; Bürk K; den Dunnen W; Reischl G; Korf HW; Brunt ER; Rüb U
Brain; 2015 Nov; 138(Pt 11):3316-26. PubMed ID: 26362908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
